Neil Kumar’s BridgeBio team locks in a $2.4B partnership as their next drug gets a snap review at the FDA
BridgeBio $BBIO is on a roll.
At the end of February, they won an approval for their first drug, a therapy used to treat extremely rare cases of molybdenum cofactor deficiency type A. In the middle of the month, there was positive proof-of-concept data for another one of its subs, Calcilytix, for ADH1.
And today they’re wrapping a busy, buzzy month with a $2.4 billion alliance to roll out their next drug in the US — infigratinib — which looks to be in the label-writing stage at the FDA as regulators set up a chip shot on a near-term approval.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.